Focus medication-assisted treatment of opioid addiction on people who have been incarcerated.
Asthma is a common chronic respiratory disease affecting nearly 8% of the U.S. population. Fractional exhaled nitric oxide (FeNO) is a noninvasive biomarker for T2-driven (i.e., allergic) airway inflammation that could be used to improve diagnosis, optimize inhaled corticosteroid dosing, and monitor adherence.
Contractor has challenges to overcome in turning a dead parrot into a phoenix.
Antibiotic resistance increases the cost of treating a bacterial infection by $1,383 and adds $2.2 billion to the country’s health care spending. Inpatient care is the biggest contributor to the incremental cost. Also costs related to antibiotic resistance were higher for older people and those in poor health.
Three quarters of the original ACOs that remain in the MSSP are still in Track 1. The Trump administration is tired of waiting for them to take on two-sided risk.
In a last-minute filing, the attorney general elected not to defend the health care law. The legal arguments in Texas v. Azar hinge on severability and legislative intent.
Public opposition would be unseemly, so insurers and hospitals work behind the scenes against price transparency.
Researchers used callers, posing as the uninsured, to call primary care offices. They got appointments if they could pay the fee. Things changed, however, if the callers tried to work out a deal by which they would pay in installments. Far fewer callers could get appointments in such cases.
Frequent shift work, particularly at night, increases type 2 diabetes risk factors, according to a study in Diabetes Care. Researchers at Brigham and Women’s Hospital in Boston looked at the impact on 270,000 people who currently work the night shift, using data from the UK Biobank.
Clinical benefits associated with new cancer therapies do not justify the high prices for the medications, and some value-based payment system is needed, according to a study published in the Journal of Oncology Practice. That’s especially true regarding incremental costs, the difference in total drug price between the novel medications and standard treatment.